Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrodin for Prevention of Post-CPB Cognitive Decline
NCT00297245Phase 4Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Feb 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of gastrodin in No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity, sponsored by Huazhong University of Science and Technology. Primary endpoint: Incidence of Cognitive Decline. Status: unknown.
02
Drugs
gastrodin
03
Conditions
No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT00297245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297245.